These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 35431172)

  • 21. Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction.
    Schwartz GG; Giugliano RP
    Curr Opin Lipidol; 2022 Jun; 33(3):147-159. PubMed ID: 35695614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sex Differences in the Density of Lipidic Plaque Materials: Insights From the REASSURE-NIRS MultiCenter Registry.
    Kataoka Y; Nicholls SJ; Puri R; Kitahara S; Kiyoshige E; Nishimura K; Murai K; Iwai T; Sawada K; Matama H; Honda S; Takagi K; Fujino M; Yoneda S; Otsuka F; Nishihira K; Takamisawa I; Asaumi Y; Noguchi T
    Circ Cardiovasc Imaging; 2023 May; 16(5):e015107. PubMed ID: 37161775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study.
    Räber L; Taniwaki M; Zaugg S; Kelbæk H; Roffi M; Holmvang L; Noble S; Pedrazzini G; Moschovitis A; Lüscher TF; Matter CM; Serruys PW; Jüni P; Garcia-Garcia HM; Windecker S;
    Eur Heart J; 2015 Feb; 36(8):490-500. PubMed ID: 25182248
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
    Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Results of the GLAGOV trial.
    Nissen SE; Nicholls SJ
    Cleve Clin J Med; 2017 Dec; 84(12 Suppl 4):e1-e5. PubMed ID: 29281604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study.
    Boccara F; Kumar PN; Caramelli B; Calmy A; López JAG; Bray S; Cyrille M; Rosenson RS;
    J Am Coll Cardiol; 2020 May; 75(20):2570-2584. PubMed ID: 32234462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolocumab attenuate pericoronary adipose tissue density via reduction of lipoprotein(a) in type 2 diabetes mellitus: a serial follow-up CCTA study.
    Yu MM; Zhao X; Chen YY; Tao XW; Ge JB; Jin H; Zeng MS
    Cardiovasc Diabetol; 2023 May; 22(1):121. PubMed ID: 37217967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy evaluation of PCSK9 monoclonal antibody (Evolocumab) in combination with Rosuvastatin and Ezetimibe on cholesterol levels in patients with coronary heart disease (CHD): A retrospective analysis from a single center in China.
    Liu Y; Han B
    Transpl Immunol; 2022 Apr; 71():101444. PubMed ID: 34375677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial.
    Wiviott SD; Giugliano RP; Morrow DA; De Ferrari GM; Lewis BS; Huber K; Kuder JF; Murphy SA; Forni DM; Kurtz CE; Honarpour N; Keech AC; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2020 Jul; 5(7):787-793. PubMed ID: 32347885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial.
    Deedwania P; Murphy SA; Scheen A; Badariene J; Pineda AL; Honarpour N; Keech AC; Sever PS; Pedersen TR; Sabatine MS; Giugliano RP
    JAMA Cardiol; 2021 Feb; 6(2):139-147. PubMed ID: 32785614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels.
    Kataoka Y; Hammadah M; Puri R; Duggal B; Uno K; Kapadia SR; Murat Tuzcu E; Nissen SE; Nicholls SJ
    Atherosclerosis; 2015 Oct; 242(2):490-5. PubMed ID: 26298740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Evolocumab in Reducing Low-Density Lipoprotein Cholesterol Levels in Chinese Patients with Non-ST-segment Elevation Acute Coronary Syndrome.
    Xu X; Chai M; Cheng Y; Peng P; Liu X; Yan Z; Guo Y; Zhao Y; Zhou Y
    Curr Vasc Pharmacol; 2021; 19(4):429-437. PubMed ID: 32543364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
    Nissen SE; Stroes E; Dent-Acosta RE; Rosenson RS; Lehman SJ; Sattar N; Preiss D; Bruckert E; Ceška R; Lepor N; Ballantyne CM; Gouni-Berthold I; Elliott M; Brennan DM; Wasserman SM; Somaratne R; Scott R; Stein EA;
    JAMA; 2016 Apr; 315(15):1580-90. PubMed ID: 27039291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome.
    Hao Y; Yang YL; Wang YC; Li J
    Int Heart J; 2022 Jul; 63(4):669-677. PubMed ID: 35831153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A retrospective nationwide analysis of evolocumab use in Sweden and its effect on low-density lipoprotein cholesterol levels.
    Svensson MK; James S; Ravn-Fischer A; Villa G; Schalin L; Cars T; Gustafsson S; Hagström E
    Ups J Med Sci; 2024; 129():. PubMed ID: 38327639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment.
    Stiekema LCA; Stroes ESG; Verweij SL; Kassahun H; Chen L; Wasserman SM; Sabatine MS; Mani V; Fayad ZA
    Eur Heart J; 2019 Sep; 40(33):2775-2781. PubMed ID: 30561610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER.
    Sabatine MS; De Ferrari GM; Giugliano RP; Huber K; Lewis BS; Ferreira J; Kuder JF; Murphy SA; Wiviott SD; Kurtz CE; Honarpour N; Keech AC; Sever PS; Pedersen TR
    Circulation; 2018 Aug; 138(8):756-766. PubMed ID: 29626068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial.
    Bohula EA; Marston NA; Ruzza A; Murphy SA; De Ferrari GM; Diaz R; Leiter LA; Elliott-Davey M; Wang H; Bhatia AK; Giugliano RP; Sabatine MS
    Am Heart J; 2024 Mar; 269():179-190. PubMed ID: 38160917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implications of GLAGOV study.
    Nicholls SJ; Puri R
    Curr Opin Lipidol; 2017 Dec; 28(6):465-469. PubMed ID: 28937411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction.
    Lou B; Liu H; Luo Y; Jiang GT; Wu H; Wang C; Wu Y; Zhou B; Yuan Z; She J; Liu J
    Lipids Health Dis; 2022 Oct; 21(1):105. PubMed ID: 36280861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.